Ikena Oncology, Inc.
IKNA
$1.10
-$0.02-1.79%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 659.00K | 1.84M | 3.85M | 9.16M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 659.00K | 1.84M | 3.85M | 9.16M |
| Cost of Revenue | 30.48M | 40.17M | 48.01M | 52.76M | 58.67M |
| Gross Profit | -30.48M | -39.51M | -46.16M | -48.91M | -49.51M |
| SG&A Expenses | 23.68M | 24.38M | 25.63M | 25.65M | 24.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.55M | 64.95M | 74.04M | 79.39M | 84.58M |
| Operating Income | -54.55M | -64.29M | -72.20M | -75.55M | -75.42M |
| Income Before Tax | -49.08M | -59.66M | -66.78M | -70.23M | -68.33M |
| Income Tax Expenses | 152.00K | -63.00K | -73.00K | -135.00K | -162.00K |
| Earnings from Continuing Operations | -49.23 | -59.60 | -66.71 | -70.09 | -68.17 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.23M | -59.60M | -66.71M | -70.09M | -68.17M |
| EBIT | -54.55M | -64.29M | -72.20M | -75.55M | -75.42M |
| EBITDA | -54.06M | -63.58M | -71.34M | -74.54M | -74.40M |
| EPS Basic | -1.02 | -1.24 | -1.43 | -1.58 | -1.63 |
| Normalized Basic EPS | -0.58 | -0.72 | -0.85 | -0.95 | -1.02 |
| EPS Diluted | -1.02 | -1.24 | -1.43 | -1.58 | -1.63 |
| Normalized Diluted EPS | -0.58 | -0.72 | -0.85 | -0.95 | -1.02 |
| Average Basic Shares Outstanding | 193.03M | 192.65M | 187.83M | 178.86M | 166.86M |
| Average Diluted Shares Outstanding | 193.03M | 192.65M | 187.83M | 178.86M | 166.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |